Department of Oriental Neuropsychiatry, Dong-eui University College of Korean Medicine, Busanjin-gu, Busan, Republic of Korea.
KM Science Research Division, Korea Institute of Oriental Medicine, Yuseong-gu, Daejeon, Republic of Korea.
Medicine (Baltimore). 2023 Nov 3;102(44):e34796. doi: 10.1097/MD.0000000000034796.
Suicide is the leading cause of death worldwide. Herbal medicine (HM) has been reported to be related to clinical improvement of some risk factors for suicide including depression. This systematic review aimed to comprehensively investigate the effectiveness and safety of HM on suicidal behaviors.
Fifteen electronic databases were searched to search relevant intervention studies, up to September 2022. The methodological quality of the included studies was assessed using the modified Cochrane risk-of-bias tool. In the included studies, outcome on suicidal behavior were analyzed, and the effect sizes were presented as mean differences (MDs) or risk ratios (RRs) with their 95% confidence intervals (CIs) through meta-analysis. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
A total of 13 randomized controlled trials (RCTs) were included in this review. Two RCTs of HM in patients with suicidal behavior found significant benefits of HM as an adjunct to fluoxetine or cognitive therapy in improving symptoms of depression. In 11 RCTs of HM in patients with other conditions, there was no statistically significant difference between HM and antidepressants in cognitive disturbance (MD, 0.12; 95% CIs, -0.20 to 0.45), a subscale of the Hamilton Rating Scale for Depression (HAMD), and suicidal ideation (0.18; -0.16 to 0.53), an item of HAMD. The overall quality of the included studies was poor. The strength of evidence assessed by GRADE was low or very low.
Though some of the studies reported significant benefits of HM in improving suicidal behavior in patients with depression, further clarification on some unsolved questions is needed in future well-designed clinical trials.
自杀是全球范围内导致死亡的主要原因。据报道,草药(HM)与一些自杀风险因素的临床改善有关,包括抑郁。本系统评价旨在全面调查 HM 对自杀行为的有效性和安全性。
检索了 15 个电子数据库,以查找相关的干预研究,截止日期为 2022 年 9 月。使用改良 Cochrane 偏倚风险工具评估纳入研究的方法学质量。在纳入的研究中,分析了自杀行为的结局,并通过荟萃分析以均数差(MD)或风险比(RR)及其 95%置信区间(CI)表示效应量。使用推荐评估、制定与评价(GRADE)方法评估证据强度。
本综述共纳入 13 项随机对照试验(RCT)。两项 HM 治疗自杀行为的 RCT 发现,HM 作为氟西汀或认知疗法的辅助治疗,可显著改善抑郁症状。在 11 项 HM 治疗其他疾病患者的 RCT 中,HM 与抗抑郁药在认知障碍(MD,0.12;95%CI,-0.20 至 0.45)和汉密尔顿抑郁量表(HAMD)的一个子量表以及自杀意念(0.18;95%CI,-0.16 至 0.53)方面无统计学差异,HAMD 的一个项目。纳入研究的总体质量较差。GRADE 评估的证据强度为低或极低。
尽管一些研究报告 HM 在改善抑郁症患者自杀行为方面有一定益处,但未来还需要在精心设计的临床试验中进一步阐明一些尚未解决的问题。